Epidemiological survey in primary care patients with chronic obstructive pulmonary disease in Greece; The EPIPTOSI study
More details
Hide details
Department of Internal Medicine, “Kyanous Stavros” Medical Centre, Athens, Greece
Medical Department, AstraZeneca SA, Greece
Corresponding author
Christos P. Carvounis   

Department of Internal Medicine, “Kyanous Stavros” Medical Centre, 102 V. Sophia Ave., 115 28 Athens, Greece
Pneumon 2012;25(4):386-394
Chronic obstructive pulmonary disease (COPD) is a chronic disease, with significant extrapulmonary effects, associated with high morbidity and mortality. The current study aimed at evaluating the characteristics, health status, management and use of health care resources of primary care patients with COPD in Greece.

EPIPTOSI was an observational, descriptive, cross-sectional study of primary care patients diagnosed with COPD. Data were collected during a single visit via a structured questionnaire. Smoking status, severity, symptoms, treatment, health care resource utilization and the patients’ perceptions of health status and treatment were recorded.

The 930 study patients (Male 66.5%, age 64.9±10.8 years) were classified with mild (22%), moderate (52%) and severe COPD (26%) respectively, based on the Global Initiative for Obstructive Lung Disease (GOLD) criteria, of whom 49.8% were smokers (average pack years 41.2). The average Clinical COPD Questionnaire (CCQ) score was 1.87± 1 (mild: 1.1±0.7, moderate: 1.6±0.8, severe: 2.9±1.5, p<0.01). The Geriatric Depression Scale (GDS) mean score for patients ≥65 years was 7.8±0.9, with a close correlation between CCQ score and severity of COPD. Treatment was with inhaled corticosteroids/long-acting β2-agonists combination (ICS/LABA) for 35.2% of patients and ICS/LABA plus anticholinergics for 27.0%. A total of 48.7% had visited an emergency care unit (ECU) while 26.4% required hospitalization at least once, during the last year. A significant association between COPD severity and hospitalization (OR 7.4 95% CI: 5.3-10.3, p<0.01) and ECU visits (OR 7.51 95% CI: 5.16-10.9, p<0.01) was found.

Most primary care patients with COPD had disease of moderate severity. Although their health status was relatively satisfactory, a considerable number each year visited the ECU of hospitals and were hospitalized for respiratory problems, illustrating the significant burden associated with COPD.

The authors would like to thank Vassilis Vaskantiras for the study delivery, George Kraniou from Pharmassist Ltd, who provided medical writing support and Associate Professor Elias Zintzaras who provided support in the statistical analysis. The study was supported by AstraZeneca.
Dr Christos P. Carvounis has received honoraria from Mount Sinai Medical Center and has received research grants as National Coordinator of four Phase IV local studies. He has received grants and acted as a consultant for AstraZeneca. Mr. Nikos Nikas and Dr. Elena Panitti are AstraZeneca employees.
GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Revised 2011. In; 2011.
Barnes PJ. Chronic obstructive pulmonary disease * 12: New treatments for COPD. Thorax 2003;58:803-8.
Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-21.
Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53.
Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004;364:613- 20.
Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and metaanalysis. Eur Respir J 2006;28:523-32.
Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006;27:188-207.
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
Soriano JB, Maier WC, Egger P, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000;55:789-94.
Man WD, Kemp P, Moxham J, Polkey MI. Skeletal muscle dysfunction in COPD: clinical and laboratory observations. Clin Sci (Lond) 2009;117:251-64.
Schellevis FG, Van de Lisdonk EH, Van der Velden J, Hoogbergen SH, Van Eijk JT, Van Weel C. Consultation rates and incidence of intercurrent morbidity among patients with chronic disease in general practice. Br J Gen Pract 1994;44:259-62.
Bakakos P, Kostikas K, Loukides S. COPD and comorbidities. Pneumon 2010;23:24-7.
van Manen JG, Bindels PJ, Dekker FW, CJ IJ, van der Zee JS, Schade E. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002;57:412-6.
Funk GC, Kirchheiner K, Burghuber OC, Hartl S. BODE index versus GOLD classification for explaining anxious and depressive symptoms in patients with COPD - a cross-sectional study. Respir Res 2009;10:1.
Yohannes AM, Roomi J, Baldwin RC, Connolly MJ. Depression in elderly outpatients with disabling chronic obstructive pulmonary disease. Age Ageing 1998;27:155-60.
van den Bemt L, Schermer T, Bor H, et al. The risk for depression comorbidity in patients with COPD. Chest 2009;135:108-14.
European Lung White Book. EuropeanRespiratory Society European Respiratory Society Journals, ltd 2003.
Becklake MR. Occupational exposures: evidence for a causal association with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;140:S85-91.
Balmes J, Becklake M, Blanc P, et al. American Thoracic Society Statement: Occupational contribution to the burden of airway disease. Am J Respir Crit Care Med 2003;167:787-97.
Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000;161:381-90.
Tashkin DP, Clark VA, Coulson AH, et al. The UCLA population studies of chronic obstructive respiratory disease. VIII. Effects of smoking cessation on lung function: a prospective study of a free-living population. Am Rev Respir Dis 1984;130:707-15.
Tashkin DP, Rennard S, Taylor Hays J, Lawrence D, Marton JP, Lee TC. Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients. Respir Med 2011;105:1682-90.
Global Initiative For Chronic Obstuctive Lung Disease. Global Strategy for the Diagnosis Management and Prevention of Chronic Obstructive Pulmonary Disease. Executive Summary 2007.
Stallberg B, Nokela M, Ehrs PO, Hjemdal P, Jonsson EW. Validation of the clinical COPD Questionnaire (CCQ) in primary care. Health Qual Life Outcomes 2009;7:26.
van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003;1:13.
Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der Molen T. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res 2006;7:62.
Fountoulakis KN, Tsolaki M, Iacovides A, et al. The validation of the short form of the Geriatric Depression Scale (GDS) in Greece. Aging (Milano) 1999;11:367-72.
Sheikh JI, Yesavage JA. A knowledge assessment test for geriatric psychiatry. Hosp Community Psychiatry 1985;36:1160-6.
Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
Tzanakis N, Anagnostopoulou U, Filaditaki V, Christaki P, Siafakas N. Prevalence of COPD in Greece. Chest 2004;125:892-900.
Bourbeau J, Sebaldt RJ, Day A, et al. Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J 2008;15:13-9.
Izquierdo JL, Barcina C, Jimenez J, Munoz M, Leal M. Study of the burden on patients with chronic obstructive pulmonary disease. Int J Clin Pract 2009;63:87-97.
Viejo-Banuelos JL, Pueyo-Bastida A, Fueyo-Rodriguez A. Characteristics of outpatients with COPD in daily practice: The E4 Spanish project. Respir Med 2006;100:2137-43.
Miravitlles M, Murio C, Tirado-Conde G, et al. Geographic differences in clinical characteristics and management of COPD: the EPOCA study. Int J Chron Obstruct Pulmon Dis 2008;3:803-14.
McCathie HC, Spence SH, Tate RL. Adjustment to chronic obstructive pulmonary disease: the importance of psychological factors. Eur Respir J 2002;19:47-53.
Yesavage J, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: A preliminary report. Journal of Psychiatric research 1983;17:37-49.
Coultas DB, Edwards DW, Barnett B, Wludyka P. Predictors of depressive symptoms in patients with COPD and health impact. COPD 2007;4:23-8.
Jennings JH, Digiovine B, Obeid D, Frank C. The association between depressive symptoms and acute exacerbations of COPD. Lung 2009;187:128-35.
Akazawa M, Stearns SC, Biddle AK. Assessing treatment effects of inhaled corticosteroids on medical expenses and exacerbations among COPD patients: longitudinal analysis of managed care claims. Health Serv Res 2008;43:2164-82.
Anzueto A, McLaughlin T, Stanford RH. Initial treatment regimen and risk of hospitalization in patients with chronic obstructive pulmonary disease. COPD 2004;1:205-14.
Soriano JB, Kiri VA, Pride NB, Vestbo J. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003;2:67-74.
Martin A, Rodriguez-Gonzalez Moro JM, Izquierdo JL, Gobartt E, de Lucas P. Health-related quality of life in outpatients with COPD in daily practice: the VICE Spanish Study. Int J Chron Obstruct Pulmon Dis 2008;3:683-92.
Journals System - logo
Scroll to top